Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024)

Table of Contents
Abstract Access options Additional access options: Similar content being viewed by others What is the pipeline for future medications for obesity? Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Author information Authors and Affiliations Corresponding author Supplementary information Supplementary Information Reporting Summary Rights and permissions About this article Cite this article

Abstract

People with type-2-diabetes (T2D) and chronic kidney disease (CKD), have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) independently reduce cardiovascular and kidney events. The effect of combining both is unclear. FLOW trial participants with T2D and CKD were stratified by baseline SGLT2i use (N=550) or no use (N=2,983) and randomized to semaglutide/placebo. The primary outcome was a composite of kidney failure, ≥50% eGFR reduction, kidney or cardiovascular death. The risk of the primary outcome was 24% lower in all participants treated with semaglutide vs placebo (95% confidence interval [CI] 34%, 12%). The primary outcome occurred in 41/277 (semaglutide) versus 38/273 (placebo) participants on SGLT2i at baseline (HR 1.07; 95% CI 0.69, 1.67; P=0.755), and in 290/1,490 versus 372/1,493 participants not taking SGLT2i at baseline (HR 0.73; 0.63, 0.85; P<0.001; P-interaction 0.109). Three confirmatory secondary outcomes were predefined. Treatment differences favoring semaglutide for total eGFR slope (ml/min/1.73m2/year) were 0.75 (–0.01, 1.5) in the SGLT2i subgroup and 1.25 (0.91, 1.58) in non-SGLT2i-subgroup, P-interaction 0.237. Semaglutide benefits on major cardiovascular events and all-cause death were similar regardless of SGLT2i use (P-interaction 0.741 and 0.901, respectively). The benefits of semaglutide in reducing kidney outcomes were consistent in participants with/without baseline SGLT2i use; power was limited to detect smaller but clinically relevant effects. ClinicalTrials.gov identifier: NCT03819153.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Change institution

Buy or subscribe

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

£14.99 /30days

cancel any time

Learn more

Subscribe to this journal

Receive 12 print issues and online access

£139.00 per year

only £11.58 per issue

Learn more

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (1)

What is the pipeline for future medications for obesity?

Article Open access 01 February 2024

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2)

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Article Open access 13 May 2024

Author information

Authors and Affiliations

  1. KfH Kidney Centre, München, Germany

    Johannes F. E. Mann

  2. University Hospital Erlangen, Friedrich Alexander University, Erlangen, Germany

    Johannes F. E. Mann

  3. Steno Diabetes Center Copenhagen, Herlev, Denmark

    Peter Rossing

  4. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

    Peter Rossing

  5. Department of Medicine, AHA Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL, USA

    George Bakris

  6. Novo Nordisk A/S, Søborg, Denmark

    Nicolas Belmar,Heidrun Bosch-Traberg,Thomas Idorn&Søren Rasmussen

  7. Albany Medical Center Division of Community Endocrinology, Albany, NY, USA

    Robert Busch

  8. Nephrology Division, Department of Medicine, New York University Grossman School of Medicine, and NYU Langone Health, New York, NY, USA

    David M. Charytan

  9. L’Institut du Thorax, CHU Nantes, CNRS, INSERM, Nantes Université, Nantes, France

    Samy Hadjadj

  10. Department of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium

    Pieter Gillard

  11. Department of Nephrology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain

    José Luis Górriz

  12. Department of Medicine, Universitat de València, Valencia, Spain

    José Luis Górriz

  13. Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, China

    Linong Ji

  14. Stanford Center for Clinical Research, Department of Medicine, Stanford School of Medicine, Palo Alto, CA, USA

    Kenneth W. Mahaffey

  15. Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia

    Vlado Perkovic

  16. Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University, Erlangen, Germany

    Roland E. Schmieder

  17. AdventHealth Translational Research Institute, Orlando, FL, USA

    Richard E. Pratley

  18. Division of Nephrology, University of Washington, Seattle, WA, USA

    Katherine R. Tuttle

  19. Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA

    Katherine R. Tuttle

Authors

  1. Johannes F. E. Mann

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  2. Peter Rossing
  3. George Bakris

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  4. Nicolas Belmar

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  5. Heidrun Bosch-Traberg

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  6. Robert Busch

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  7. David M. Charytan

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  8. Samy Hadjadj

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  9. Pieter Gillard

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  10. José Luis Górriz

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  11. Thomas Idorn

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  12. Linong Ji

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  13. Kenneth W. Mahaffey

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  14. Vlado Perkovic

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  15. Søren Rasmussen

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  16. Roland E. Schmieder

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  17. Richard E. Pratley

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  18. Katherine R. Tuttle

    View author publications

    You can also search for this author in PubMedGoogle Scholar

Corresponding author

Correspondence to Johannes F. E. Mann.

Supplementary information

Rights and permissions

About this article

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (4)

Cite this article

Mann, J.F.E., Rossing, P., Bakris, G. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-03133-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41591-024-03133-0

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024)
Top Articles
Online Therapy Options for Overcoming Drug Addiction
Senior Talent Acquisition Partner - Tech
Top Tier Solar Solutions Job Reviews
His Words Any Sense Figgerits
Craigslist Charleston Sc
san diego for sale "landscaping" - craigslist
Who Has Better Gas Prices: Costco or Sam's Club?
Obituaries Kankakee Daily Journal
Human Resources - Glenwood Springs, CO
TraderJoes Dayforce: Streamlining Operations For Retail Success
Urban Blight Crossword Clue
Learning Hub Inspire Brands
Latest Posts
Telehealth for Addiction (Online Rehab & Counseling Programs)
Digital Healing: Exploring the Effectiveness of Online Therapy for Addiction
Article information

Author: Rev. Porsche Oberbrunner

Last Updated:

Views: 6596

Rating: 4.2 / 5 (53 voted)

Reviews: 84% of readers found this page helpful

Author information

Name: Rev. Porsche Oberbrunner

Birthday: 1994-06-25

Address: Suite 153 582 Lubowitz Walks, Port Alfredoborough, IN 72879-2838

Phone: +128413562823324

Job: IT Strategist

Hobby: Video gaming, Basketball, Web surfing, Book restoration, Jogging, Shooting, Fishing

Introduction: My name is Rev. Porsche Oberbrunner, I am a zany, graceful, talented, witty, determined, shiny, enchanting person who loves writing and wants to share my knowledge and understanding with you.